At a glance
ClinicalIndex Comparison RecordN/ACompleted· 692 enrolled
Drug / intervention
Catheter-Directed Thrombolysis +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The PEERLESS Study
In Brief
A clinical study evaluating Catheter-Directed Thrombolysis and FlowTriever System for Pulmonary Embolism and Pulmonary Thromboembolism. Completed, enrolled 692 participants across 60 sites in 3 countries.
Detailed Summary
A prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thrombolysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Embolism, Pulmonary Thromboembolism
CountriesGermany, Switzerland, United States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartFeb 2022
Primary CompletionMar 2024
Study CompletionApr 2024
TodayJul 2026
First PostedNov 8, 2021
Enrollment StartFeb 14, 2022
Primary CompletionMar 1, 2024
Study CompletionApr 11, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.6 years ago
Interventions
Catheter-Directed Thrombolysisdevice
Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
FlowTriever Systemdevice
Mechanical thrombectomy for pulmonary embolism